Grifols, ES0171996087

Grifols stock gains analyst support on Alzheimer data and rating upgrade

Published on 09/19/2026 at 18:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock is back in focus as Wall Street Zen raised its rating to Buy on September 19, 2026, while new real-world data reinforce the company’s Ambar Alzheimer program. Investors now weigh the defensive plasma business against ongoing leverage and valuation risks.

Isometrische 3D-Grafik der Plasma-Wertschöpfungskette von Spende bis Medikament — Isometrische 3D-Illustration zeigt die Wertschöpfungskette von der Plasmaspende bis zum Medikament bei Grifols S.A. ES0171996087, Illustration mit AI erstellt.

Grifols stock (ISIN ES0171996087) opened the latest Nasdaq session at USD 7.31 on September 18, 2026, close to its 52-week low of USD 6.96 and implying a market capitalization of about USD 4.98 billion per recent price data. According to MarketBeat on September 19, 2026, Wall Street Zen has raised its stance on Grifols from Hold to Buy, even as the broader analyst consensus still points to a Reduce rating with an average target price of USD 10.00.

Analyst upgrade shifts tone around Grifols stock

As MarketBeat reports on September 19, 2026, Wall Street Zen’s upgrade to Buy stands against a backdrop where two analysts rate Grifols Hold and one rates it Sell, resulting in a consensus Reduce recommendation and an average price target of USD 10.00. With shares recently opening at USD 7.31, that target implies a potential upside of about 36.8 percent versus the latest price level, underlining the degree to which the market discounts the stock relative to the consensus valuation.

According to the same overview from MarketBeat, Grifols trades on Nasdaq under the ticker GRFS with a price-to-earnings ratio of 38.47, a price-to-earnings-growth ratio of 0.27 and a beta of 0.67, highlighting a combination of premium headline valuation and comparatively low share-price volatility. The same data show a 52-week high of USD 10.23, meaning the recent USD 7.31 level leaves the stock around 28.5 percent below its 12-month peak and just 5.0 percent above its USD 6.96 low, a range that will matter for technically minded investors.

Ambar Alzheimer program delivers new real-world evidence

Beyond the rating change, Grifols’ long-running Ambar program (Alzheimer Management by Albumin Replacement) is receiving renewed attention thanks to fresh clinical practice data. As Democrata reports in a statement dated September 19, 2026, Grifols has incorporated recent real-world clinical practice results into Ambar, expanding the evidence base on therapeutic plasma exchange with albumin replacement for patients with mild and moderate Alzheimer’s disease. According to the company’s earlier Ambar study cited by Democrata, this approach has been shown to slow disease progression by 61 percent compared with patients who did not receive the treatment, a figure that offers a concrete sense of the therapeutic potential.

According to Democrata, the Ambar program is being implemented at HM Sanchinarro Hospital in Madrid and Juaneda Clinic in Palma, in collaboration with Ace Alzheimer Center Barcelona via the Ambar Center in Barcelona, while Grifols continues discussions with other Spanish hospitals to gradually add new sites. The same report notes that new real-world results linked to Ambar are scheduled to be presented at the Annual Meeting of the Spanish Society of Neurology in Seville from November 17 to November 21, 2026, providing a visible future catalyst for scientific and investor interest.

Balance sheet structure and institutional interest shape the risk profile

While the recent rating upgrade and clinical progress offer positive signals, the financial structure remains a core element of the investment case. Data summarized by MarketBeat indicate that Grifols currently carries a debt-to-equity ratio of 1.10, a quick ratio of 0.81 and a current ratio of 2.37, underscoring both meaningful leverage and adequate short-term liquidity. For investors, the key question is whether growth in plasma-derived therapies and programs such as Ambar can outpace the cost of servicing debt and support a rerating of the shares from the present USD 7.31 zone toward the USD 10.00 average target.

The same institutional trading overview from MarketBeat shows that several investors have recently increased their positions. Tidal Investments LLC, for example, lifted its stake by 9.8 percent in the second quarter of 2026 to 1,233,082 shares valued at about USD 8.73 million, while Hennion & Walsh Asset Management raised its holding by 13.8 percent to 592,173 shares worth roughly USD 4.19 million in the same period. These moves suggest that, despite the consensus Reduce rating, parts of the institutional community are positioning for a recovery in fundamentals and valuation.

Grifols stock stays near the lower end of its trading range

Per recent Nasdaq price data mirrored in the MarketBeat snapshot, shares of Grifols closed the latest completed trading session at USD 7.31 on September 18, 2026, with the 52-week range spanning from USD 6.96 to USD 10.23. In euro terms on the Spanish market, a parallel quote from Bolsamania for the Grifols-A listing shows a price of EUR 9.542 at 17:35 on September 18, 2026, down 1.71 percent from a prior close of EUR 9.708 and within a 52-week range of EUR 8.432 to EUR 12.870, offering an additional perspective for investors who track the home-market line.